Treatment Satisfaction With Ra-223 in Japan

Exclusion Criteria

• •Participation in an investigational program with interventions outside of routine clinical practice
• •Currently receiving any chemotherapy for CRPC or any new hormone therapy (enzalutamide, abiraterone acetate) at enrolment
• •Where any of the below conditions apply:
• •* Started or switched to new androgen deprivation therapy (ADT) (e.g., LHRH agonists and antagonists, anti-androgens, estrogens,) within 4 weeks prior to enrolment or planning to start new treatment prior to 1st Ra-223 injection
• •* Treatment with anticancer-chemotherapy within previous 4 weeks, or planned before the 1st Ra-223 injection, or failure to recover from adverse events (AEs) (CTCAE Grade \>2) due to anticancer chemotherapy administered more than 4 weeks prior
• •* Systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within the previous 24 weeks
• •* Previous hemi-body external radiotherapy
• •Imminent or established spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI)
• •Presence of other maligancy at enrolment
• •Otherwise deemed incapable of participating by examining physician